The Neurology Center of Southern California
3907 Waring Road, Suite 2, 3 and 4, Oceanside, California, 92056
320 Santa Fe Drive, Suite 108, Encinitas, California, 92024
332 Santa Fe Drive, Suite 150, Encinitas, California, 92024
1955 Citracado Pkwy, Suite 102, Escondido, California, 92029
Phone: 760-631-3000
Fax: 760-631-3016

Thomas John Chippendale, M.D., Ph.D.

EDUCATION

University of California, Irvine, CA ■ 1971
B.S., Biological Sciences, Cum Laude, Research Honors in Psychobiology

University of California, Irvine, CA ■ 1972
M.S., Medical Pharmacology and Experimental Therapeutics

Princeton University, Princeton, NJ ■ 1974
M.A., Psychology, Spencer Fellow

Princeton University, Princeton, NJ ■ 1977
Ph.D., Neurosciences and Behavior, Spencer Fellow

University of California, Irvine, CA ■ 1980
M.D.

University of California, San Diego, CA ■ 1980-1981
Internship, Medical

University of California, San Diego, CA ■ 1981-1984
Residency, Neurology

LICENSURE

California Medical License Number – G46820

CERTIFICATIONS

American Board of Psychiatry and Neurology ■ 1989

American Board of Holistic Medicine ■ 2007

ACADEMIC APPOINTMENTS

Teaching Assistant, Department of Pharmacology
California College of Medicine, University of California, Irvine, ■ 1971-72

Instructor, Department of Psychology
Princeton University, Princeton, New Jersey ■ 1972-76

02/AUG/2012

ACADEMIC APPOINTMENTS CONTINUED

Instructor, Department of Anatomy, Human Neuroanatomy
University of California, Irvine, ■ 1980

Chief Resident, Department of Neurology
California College of Medicine, University of California, San Diego, ■ 1983-1984

Assistant Professor, Department of Neurosciences
University of California, San Diego, ■ 1984 – present

RELATED EXPERIENCE

Neurologist, Private Group Practice, North County Neurology Associates dba The Neurology Center, Oceanside, Encinitas, and La Jolla offices, CA ■ 1984 – Present

Neurologist, Research Center, The Research Center of Southern California, LLC. Encinitas & Oceanside, CA ■ 2007 – Present

HOSPITAL AFFILIATIONS

Tri-City Medical Center, Oceanside, California, Active Privileges ■ 07/26/1984 – Present

Chief of Staff ■ 1996 – 1997

Scripps Memorial Hospital, Encinitas, California, Active Privileges ■ 1984 – Present

Chief, Division of Neurology ■ 1993 – 95, 1998 – 2000

Chief, Division of Medicine ■ 2001 – 2008

Stroke Director ■ 2004 – Present

Physician Advisor, Case Management ■ 2003 – Present

Co-Director of Neurosciences ■ 2007 – Present

Vice Chief of Staff ■ 2008-2010

Chief Of Staff ■ 2011- Present

Scripps Memorial Hospital, La Jolla, California, ■1992 – Present

Scripps Mercy Hospital, San Diego, California, ■ 2011- Present

Scripps Mercy Hospital, Chula Vista, California, ■ 2011- Present

Scripps Health, San Diego, California, ■ 2012- Present

System Wide Director of Neuroscience, ■ 2012- Present

System Wide Stroke Director, ■ 2012- Present

UCSD, La Jolla, California, Asst. Clinical Prof. ■ 1984 – 2005

VA Medical Center, San Diego, California, Inactive Privileges. 1983- Present

PROFESSIONAL SOCIETIES

American Academy of Neurology, Member ■ 1981 – Present

San Diego Neurological Association ■ 1981 – Present

President ■ 1989 – 1990

02/AUG/2012

PROFESSIONAL SOCIETIES CONTINUED

American Society of Neuroimaging, Board of Directors ■ 1990 – 1993

San Diego Stroke Council ■ 1996 – 1999

Founder and Co-Chairman ■ 1996 – 1999

Operation Stroke ■ 1999-2002

National MS Society, San Diego Chapter, Professional Advisory Board ■ 1992 – Present

Association of California Neurologists, Charter Member ■ 1998 – Present

American Heart / Stroke Association, Board of Directors, San Diego Chapter ■ 2008-2010,

■ 2012- Present

PUBLICATIONS AND PAPERS

Chippendale, T.J., Zawolkow, G.A., Russell, R.W., and Overstreet, D.H., Tolerance to Low Acetylcholinesterase Levels: Modification of Behavior Without Acute Behavioral Change, *Psychopharmacologia*, 26, 127-139; 1972.

Chippendale, T.J., Cotman, C.W., Kozar, M.D., and Lynch, G.S., Analysis of Acetylcholinesterase Synthesis and Transport in the Rat Hippocampus: Recovery of Acetylcholinesterase Activity in the Septum and Hippocamus after Administration of Diisopropylfluorophosphate, *Brain Research*, 81, 485-496; 1974.

Kozar, M.D., Overstreet, D.H., **Chippendale, T.J.**, and Russell, R.W., Changes of Cholinesterase Activity in Three Major Brain Areas and Related Changes in Behavior Following Acute Treatment with Diisopropylfluorophosphate, *Neuropharmacology*, 15, 291-298; 1976.

Haubrich, D.R., **Chippendale, T.J.**, and Wang, P.L.F., The Role of Dietary Choline in Acetylcholine Synthesis, *Journal of Neurochemistry*, 27, 1235-1313; 1976.

Haubrich, D.R., and **Chippendale, T.J.**, The Regulation of Acetylcholine Synthesis in Nervous Tissue, Mini-review, *Life Sciences*, 20, 1465-1478; 1977.

Squires, K., **Chippendale, T.J.**, and Starr, A., Serial Changes in Cognitive Components of Auditory Evoked Potentials in Dementing Illness, *Annuals of Neurology*, 8, 115, 1980.

Chippendale, T.J., Meralgia Paresthetica, *Western Journal of Medicine*, 132, 145-146; 1980.

Goodin, D.S., Starr, A., **Chippendale, T.J.**, and Squires, K. C., Sequential Changes in the P3 Component of the Auditory Evoked Potential of Confusional States and Dementing Illnesses, *Neurology*, 33, 1215-1218; 1983.

Collaborating Clinical Centre, North County Neurology Associates, Oceanside: **T. Chippendale**, M. Lobatz, E. Diamond, J. Schim, M. Sadoff. "A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE)", CAPRIE Steering Committee, *The Lancet* Vol 348 No 9038, 1329-1339, November 16, 1996.

Participating Clinical Center: Tri-City Medical Center, **T. Chippendale**, E. Diamond, M. Lobatz, D. Murphy, D. Rosenberg, T. Ruel, M. Sadoff, J. Schim, J. Schleimer. "Tissue Plasminogen

Activator for Acute Ischemic Stroke," The *New England Journal of Medicine*, Vol. 333 No 24, 1581-1587, December 14, 1995.

Sherman D.G., Atkinson R.P., **Chippendale T.J.**, et al., Intravenous Ancrod for Treatment of Acute Ischemic Stroke, The STAT Study: A Randomized Controlled Trial, *JAMA,* 2000; 283:2395-2403, May 10, 2000

SPARCLE Investigators, "A Double-Blind, Randomized, Placebo-Controlled Study of Atorvastatin as Prevention of Cerebrovascular Events in Patients with a Previous Transient Ischemic Attack (TIA) or Stroke" N Engl J Med 2006; 335:549-59

Andrew M Blumenfeld, M.D.; Jack D Schim, M.D.; **Thomas J Chippendale, M.D.** "Botulinum Toxin Type A and Divalproex Sodium for Prophylactic Treatment of Episodic or Chronic Migraine." *HEADACHE The Journal of Head and Face Pain*, Vol. 48 No 2, 210-220, February 2008

Justin A Zivin, Gregory W. Albers, Natan Bornstein, **Thomas Chippendale**, Bjorn Dahlof, Thomas Devlin, Marc Fisher, Werner Hacke, William Hold, Sanja Ilic, Scott Kasner, Robert Lew, Marshall Nash, Julio Perez, Marilyn Rymer, Peter Schellinger, Dietmar Schneider, Stefan Schwab, Roland Veltkamp, Michael Walker, Jackson Streeter and for the NEST-2 Investigators. *"Effectiveness and Safety of Transcranial Laser Therapy for Acute Ischemic Stroke"; Stroke Journal of the American Heart Association* [Online] Available http://stroke .ahajournals.org, February 20, 2009

Morrow,DA, Braunwald,E, et al, TRA2P-TIMI 50 Steering Committee and Investigators (including **TJ Chippendale**). "Vorapaxar in the Secondary Prevention of Atherothrombotic Events" NEJM, 2012 Apr 12,366(15):1404-13.

RESEARCH ACTIVITIES

Alzheimer's disease

Suloctidil study for Alzheimer's Disease, Monsanto, Sub Investigator, 1987

D97-019 "Metrifonate investigational nationwide trial (M.I.N.T.)", Principal Investigator, 1997

Parke-Davis 979-14 "A 26-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center with a sustained active phase study of Milameline (CI-979/RU 35926) in patients with probable Alzheimer's Disease", Sub-Investigator, 1995 - 1996.

Parke-Davis 979-16 "Open label extension of "A 26-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center with a sustained active phase study of Milameline (CI-979/RU 35926) in patients with probable Alzheimer's Disease", Sub-Investigator, 1996-1997

970-68-23 "A 16-week randomized, double-blind, placebo-controlled parallel-group, dose-response multi-center study of Tacrine (CI-970) once-a-day formulation (Tacrine GITS) with a 16-month open-label extension in patients with dementia of the Alzheimer's type", Sub-Investigator, 1996 - 1997

970-68-23 "Open label extension of "A 16-week randomized, double-blind, placebo-controlled parallel-group, dose-response multi-center study of Tacrine (CI-970) once-a-day formulation (Tacrine GITS) with a 16-month open-label extension in patients with dementia of the Alzheimer's type", Sub-Investigator, 1996-1997.

Alzheimer's *continued*

GAL-INT-11 "A randomized double blind placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment (MCI) clinically at risk for development of clinically probably Alzheimer's Disease", Principal-Investigator, 2001 – 2003

TVP1012-A001-201- A 1-Year, double-blind, randomized, placebo-controlled study of Rasagiline 1 mg and 2 mg added to Aricept 10 mg daily in patients with mild to moderate dementia of the Alzheimer's type. Sub-Investigator, 2005.

VP-AD-301 "A Double-Blind Placebo-Controlled Study of VP4896 for the Treatment of Mild to Moderate Alzheimer's Disease". Sub-Investigator, 2006.

PRX-03140 "A Randomized, Double-Blind, Placebo Controlled, Phase IIa Study to Assess the Short-Term Effects of PRX-03140 Alone and in Combination with Donepezil in Subjects with Mild Alzheimer's Disease". Sub-Investigator, 2006

ELN115727-301 & 302 "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trail of Bapineuzumab (AAB-001,ELN115727 in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein E ε4 Non- Carriers (301) or Carriers (302)", 2008

ELN115727-351 "A Phase 3 Extension, multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Alzheimer's Disease who Participated in Study ELN115727-301 or in Study ELN115727-302" – 2009

AAB-001-SC-ALZ-2003 " A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects with Mild to Moderate Alzheimer's Disease" - 2010

Epilepsy

3310101018 "A multi-center, double-blind, placebo-controlled, randomized, parallel-group trial of Rufinamide as adjunctive therapy in patients with inadequately controlled primary generalized tonic-clonic seizures", Sub Investigator, 1997 - 2001

M92-813 "Tiagabine HCl administration in patients with epilepsy", Principal Investigator, 1995 – 1998

E2080-A001-301 "A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures". Sub Investigator, 2006

Migraine

M/3275/0008 "Oral Almotriptan (LAS31416) vs. Oral Sumatriptan in a double Blind, Randomized, Parallel Group Study of Cost-Effectiveness and Quality of life in Migraine." -Sub-Investigator- 1988-1999.

M/3275/0011 "A long-term open label safety study of Almotriptan 12.5 mg orally in migraine patients". -Sub-Investigator- 1988-1999.

S2WA3003 "A randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of oral Naratriptan in the acute treatment of four migraine attacks." –Principal Investigator- 1995-96.

02/AUG/2012

Migraine *continued*

S2b-350 “Imitrex (Sumatriptan Succinate) injection, post-marketing surveillance study.” -Sub-Investigator- 1995.

S2WA 3001 - “A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of Four Doses of Oral Naratriptan in the Acute Treatment of a Single Migraine Attack” -Sub-Investigator- – 1995.

S2WA 1007 - “A Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Oral Naratriptan in Migraine Subjects” -Sub-Investigator- 1995-1996.

CN115-0038—22 “An open label long-term trial evaluating the safety of BMS-180048 150mg in the treatment of patients with migraine headache with or without aura.” -Sub-Investigator- 1996.

ALN-INT-16 “The efficacy and safety of Alniditan (1.4 or 1.8 mg SC) vs. Sumatriptan (6 mg SC) in the acute treatment of migraine: A randomized, double-blind, placebo-controlled, single-dose trial.” -Sub-Investigator- 1996.

ALN-USA-18 “Open evaluation of the long-term efficacy, safety and tolerability of 1.4 mg SC Alniditan in the acute treatment of migraine attacks.” -Sub-Investigator- 1996-97.

SUMA4015 “A randomized, double-blind, placebo-controlled study to evaluate the impact of sumatriptan injection on workplace productivity loss due to migraine” (Imitrex). -Sub-Investigator- 1996 - 1997.

CN102-021 - “A Randomized, Double-Blind Trial Comparing the Safety and Efficacy of Butorphanol Tartrate Nasal Spray Versus Acetaminophen and Codeine Phosphate Capsules Versus Placebo in Patients with Acute Migraine Headache Pain” -Sub-Investigator- 1996.

CN115-038-031 - “An Open Label Long-Term Trial Evaluating the Safety of BMS-180048 150 mg in the Treatment of Patients with Migraine Headache With or Without Aura” -Sub-Investigator- 1996.

SUMA 4014 **-** “A Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Efficacy of a Second Sumatriptan Succinate Tablet (25 or 50 mg.) In the Acute Treatment of Migraine” -Sub-Investigator- 1996-1997.

VML 251/96/07 “A double-blind placebo-controlled, parallel-group study to assess the efficacy and safety of up to two doses of VML251 in the acute treatment of migraine.” (Vanguard) -Sub-Investigator- 1997.

311c90 **-** “A Double Blind, Randomized Comparison of Zolmatriptan and Sumatriptan in the Acute Treatment of Multiple Migraine Headaches” -Sub-Investigator- 1997.

VML251/90/06 - “A Double Blind, Placebo Controlled, Parallel Group Study to Assess the Efficiency and Safety of a Single Dose of VML251 (2.5mg) in the Acute Treatment of Migraine”. -Sub-Investigator- 1997.

LY303870 **-** “Dose Comparison of LY303870 in the Long Term Prophylaxis of Migraine” -Sub-Investigator- 1997.

Migraine *continued*

1042-0117.12 “A Double-Blind, Parallel, Placebo-Controlled, Single-Dose, Outpatient Study of Ganaxolone for the Treatment of Migraine With or Without an Aura.” -Sub-Investigator- 1998-2000.

191622-024-00 “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of three dosages of BOTOX◆ (Botulinum Toxin, Type A) Purified Neurotoxin Complex for the Prophylactic Treatment of Migraine Headaches.” -Sub-Investigator- 2000.

SUM40274 – “A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Attack Evaluation of Sumatriptan 50mg and 100mg Versus Placebo During a Migraine Headache at the First Sign of Pain.” -Sub-Investigator- 2000.

A1601022 “A Multicenter Trial to Evaluate the Efficacy, Tolerability and Subject Satisfaction with Eletriptan in the Treatment of Migraine Headache Attacks in Neurology Practices.” -Sub-Investigator- 2000

191622-036 – “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Continuation of Benefit of Two Dosages of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Prophylactic Treatment of Migraine Headaches.” -Sub-Investigator- 2002.

MT100-304 – “A Single Dose, Double-Blind, Safety and Efficacy Study of MT 100, Metoclopramide Hydrochloride and Naproxen Sodium in Subjects With Acute Migraine Attacks.” –Principal Investigator- 2000.

SUM40276 – “An Open-label, Long-term Observational Study of the Safety and Tolerability of Sumatriptan Nasal Spray in the Treatment of Migraine in Adolescents”, Sub-Investigator, 2001

061-00 – “A Randomized, Open-Label, Parallel-Groups, Outpatient Study to Examine the Long Term Safety and Tolerability of Rizatriptan 5mg P.O. for the Acute Treatment of Migraine in Adolescents.” -Sub-Investigator-2001.

191622-037-01 – “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of BOTOX® (Botulinum Toxin Type A) Parodied Neurotoxin Complex for the Prophylactic Treatment of Migraine Headaches in the Episodic Migraine Population.” Sub-Investigator, 2004

191622-038 – “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Prophylactic Treatment of Headaches in the Chronic Headache Population.” – Sub-Investigator – 2004

CAPSS-155 – “A Comparison of the Efficacy and Safety of Topamax® (Topiramate) Tablets Versus Placebo for the Prophylaxis of Migraine.” – Sub-Investigator – 2001

MT100-308 – “A Double Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of MT 100 Versus Over-Encapsulated Sumatriptan in Subjects with Acute Migraine Attacks.” – Sub-Investigator – 2001

MT100-402 – “A Double Blind, Randomized Placebo-Controlled, Study to Evaluate the Safety and Efficacy of MT 100 for the Treatment of Migraine in Subjects Who Are Intolerant to 5-HT Agonists or Have Cardiovascular Risk Factors.” – Sub-Investigator – 2001

Migraine *continued*

MT100-401A – “A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Two Tablet Dose of MT 100 for Treatment of Migraine in Imitrex® Non-responders.” – Sub-Investigator – 2001.

MT 300-302 – “A Randomized-Double-Blind, Placebo Controlled Evaluation of the Safety and Efficacy of MT 300 in the Acute Treatment of Migraine.” – Sub-Investigator – 2003.

SUM40298 – “A Randomized, Double-Blind, Placebo-Controlled, Single Attack, Parallel-Group Evaluation of the Efficacy of Sumatriptan 50mg Tablets versus Placebo in the Treatment of Self-

Described and/or Physician-Diagnosed Sinus Headaches that Meet International Headache Society (HIS) Criteria for Migraine Headache.” – Sub-Investigator – 2002.

VML251/00/02 – “A Double-Blind, Placebo-Controlled, Three-Way Crossover clinical Study to Assess the Safety and Efficacy of Two Dose Regimens of Frovatriptan, Compared with Placebo, in Preventing Menstrually Associated Migraine (MAM) Headaches.” – Sub-Investigator – 2002-2003.

311CUS/0022 “A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (Zomig) Nasal Spray in the Acute Treatment of Adult Subjects with Migraine” – Sub-Investigator – October 2002 – 2003

E2020-A001-211 “A 20-week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Preliminary Study to Evaluate The Efficacy and Safety of Two Fixed Doses (5mg and 10 mg) of Donepezil Hydrochloride (E2020) in Migraine Prophylaxis – Sub-Investigator – July 2002-November 2002.

SUM40299 “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Tolerability of Oral Sumatriptan 25mg, 50mg, and 100mg tablets for a Single Moderate or Severe Headache in Adults Diagnosed with Migrainous Disorder (HIS 1.7) – Principal Investigator – October 2002.

MT300-401 “A Muticenter Randomized, Single-Blind, Evaluation of Three Injectable Anti-Migraine Drugs” - Sub-Investigator – February 2003

CL1776-005 – “A Phase 2 Safety and Efficacy Study of NPS 1776 for the Acute Treatment of Migraine Headaches” – Sub Investigator – 2004

001 – “A Randomized, Evaluator-Masked Trial to Evaluate the Efficacy of Botox Compared with Depakote in Migraine Prevention” – Principal Investigator – 2004

3420AG1 – “Program to Assess Treatment Strategies: A Botox Observational Program” – Sub Investigator – 2003

MT400-303 “An Open-label, Repeat Dose Study of the Safety of Combo Formulation in the Treatment of Multiple Episodes of Acute Migraine Over 12 Months”, Sub – Investigator, 2004

065-00- (Maxalt) “A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10-mg Tablet Administered Early During a Migraine Attack While the Pain is Mild”, Sub-Investigator, 2004

02/AUG/2012

Migraine *continued*

MT400-301 (POZEN) “A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches”, Sub-Investigator, 2004

VML251-3MRM/02 “A double-blind, placebo-controlled, parallel group study, with an open-label extension phase, to assess the efficacy, tolerability and safety of oral frovatriptan in the prevention of menstrually related migraine (MRM) headaches in a “difficult to treat” population. Sub-Investigator, 2005.

E2007-A001-210- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 in Migraine Prophylaxis. Sub-Investigator, 2005.

A Single-Center, Double-Blind Comparison of BOTOX® (Botulinum Toxin Type A) and DEPAKOTE® for the Prophylactic Treatment of Migraine Headaches- Pilot Study. Sub-Investigator. 2004

“A Single-Center, Double-Blind Comparison of Botox and Topiramate for the Prophylactic Treatment of Chronic Migraine Headache”. 2005

1602 “A Multi-Center, Randomized, Single-Blind, Controlled Study to Obtain Preliminary Safety and Efficacy Data for ONS Treatment of Chronic Migraine Headache”. Sub-Investigator, 2005

191622-079/080 “A Multicenter Study Evaluating the Efficacy and Safety of Botox Purified Neurotoxin complex as Headache Prophylaxis In Migraine Patients with 15 or More headache Days per 4-Week Period in a 24 week, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Phase Followed by a 32 Week Open-Label Phase”. Sub-Investigator 2006

TRX103632/635 “A Randomized, Double-Blind, Multi-Center, Placebo Controlled, Cross-Over Study to Determine the Consistency of Response for TREXIMA (Sumatriptan 85mg/Naproxen Sodium 500mg) in the Acute Treatment of Multiple Migraine Attacks”. Sub-Investigator 2006

TRX106573 “A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Cross-Over Study of Trexima® in Migraine Subjects Who Report Poor Response or Intolerance to Relpax® “. Sub-Investigator, 2006

“The Effect of BOTOX® for the Treatment of Episodic Migraine Headaches in Patients who Demonstrate Poor Response to Triptans” Sub-Investigator 2006

NL-2006-001 “A Phase III Randomized, Double-Blind, Parallel Group, Sham-Controlled Study Evaluating the Efficacy and Safety of Non-Invasive, Non-Repetitive Transcranial TMS Stimulation (TMS) for the Acute Preemptive Treatment of the Aura Phase of Migraine Headache”. Sub-Investigator 2007

TON/03/07-CLIN “ Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study Of The Efficacy And Tolerability Of Tonabersat In The Prophylaxis Of Migraine Headache And Open Label Extension” Sub Investigator 2007

BTX0805”Safety and Efficacy of Botulinum Neurotoxin Type A in the Treatment of Forward Head Posture with Associated Chronic Tension Type Headache using a Novel Fixed sit Injection Paradigm - 2009.

02/AUG/2012

Migraine *continued*

NXN-188-203 " A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache with Aura" Sub Investigator 2009

NXN-188-204 " A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache without Aura" Sub Investigator 2009

0462-082-00 " A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents" Sub Investigator 2010

Multiple Sclerosis

01-9002 - "A Long-Term Open Label Study to Evaluate the Safety of Copolymer I and to Extend Its Availability to Patients with Relapsing-Remitting Multiple Sclerosis, SubInvestigator, 1994-97

BL01-3112 - "Phase III, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of Betaseron in Patients with Secondary-Progressive Multiple Sclerosis" - Sub-Investigator- 1996-1997

6002i - "Phase II Study of Hu23F2G in Acute Exacerbation of Multiple Sclerosis" - Sub-Investigator - 1997

IAMS05- "Phase 2 Study of Hu23F2G Multi-dose in Acute Exacerbation of Multiple Sclerosis." -Sub-Investigator- 1998-2000

CAMMS223 – "A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low and High Dose CAMPATH (MABCAMPATH) and High Dose Rebif in Patient with Early, Active Relapsing-Remitting Multiple Sclerosis." – Principal Investigator – 2003

9006- (TEVA) "A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of 40mg of Copaxone in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients", Principal-Investigator, 2004

A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis with optional extension phase ProtocolNo.: CFTY720D2309
Extension to CFTY720D2309 (A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5mg and 1.25mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis ", Principal Investigator - 2006

28821 "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Oral Cladribine in Subjects with a First Clinical Event at High Risk of Converting to MS." – 2006

02/AUG/2012

Multiple Sclerosis *Continued*

CFTY720D2302 “ A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferon β-1a (Avonex®) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase “, Principal Investigator - 2007

MPB8298-SP-03 “A Double-Blind, Placebo Controlled Multi-Center Study To Evaluate The Efficacy and Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis Sub Investigator 2007

ACT10573 “A Double Blind, Placebo-Controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients with Multiple Sclerosis.” – 2008

29652 “A 12 week, Phase IIIb, Open-Label, Single-Arm, Multicenter Trial to Evaluate Ease of use of an Electronic Autoinjector (RebiSmart™) for Self-Injection in Subjects with Relapsing Multiple Sclerosis (RMS) treated with Rebif® 44mcg Subcutaneously three times a week.” – 2009

DRI10566 “A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerablility of Nerispirdine 50mg, 100mg, and 200mg in Patients with Multiple Sclerosis” – 2009

H9B-MC-BCDJ (a) –Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis

Nerispirdine (HP184) - Clinical Trial - ACT10573: A double-blind, placebo-controlled, randomized crossover, activity study of oral doses of 50 mg and 400 mg nerispirdine on visual function in patients with multiple sclerosis IND # 61,494” - 2010

101MS325 “A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis” – 2010

CFTY720DUS01 “A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC)” – 2010

EFC6058 “ A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta” - 2010

Pain

BTOX 144-8051 “A multicenter, double-blind, placebo-controlled, parallel, graduated-dose clinical trial of Botox (botulinum toxin type A) purified neurotoxin complex for the treatment of chronic low back muscle spasm.” -Sub-Investigator- 1996-97.

BTOX-145-8051 “A multicenter, double-blind, placebo-controlled, parallel, graduated-dose clinical trial of Botox (Botulinum Toxin Type A) purified neurotoxin complex for the treatment of chronic low back muscle spasm” -Sub-Investigator- 1997.

02/AUG/2012

Pain *Continued*

A1A20004 “A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Tolerability of a 14 Day Treatment Course of GW493838 50mg Compared to Placebo in Subjects with Peripheral Neuropathic Pain. – Sub-Investigator – November 2002 – 2003.

Parkinson’s Disease

HL18317 “An open, randomized, multicenter study to assess the efficacy and safety of 1.25mg O.D. and 5 mg B.D. (or 10mg O.D.) Zydis Selegiline in the control of symptoms of Parkinson’s Disease in patients stabilized in a regimen including Selegiline.” -Sub-Investigator- 1996

NR15440/M35016 **“**Non-comparative Open Label Study to Identify Tasmar Dosage Regimen in Non-Fluctuating Parkinson’s Disease Patients Treated with Sinemet; with Follow-Up Extension of Tasmar” -Sub-Investigator- 1997.

Z/SEL/95/008 EXTENSION – “An open, multicenter parallel group continuation study to assess the safety of 1.25mg qd and 10mg qd Zydis Selegiline in the control of symptoms of Parkinson’s disease in patients stabilized on a regimen including Selegiline.” –Principal Investigator- 1998.

“A/SEL/97/026, A randomized, double-blind, parallel-group study to compare the safety and efficacy of Zydis Selegiline 1.25 to 2.5 mg Q.D. with placebo as an adjunct in the management of Parkinsonian patients being treated with Levodopa who exhibit deterioration in the quality of their response to this therapy. “-Sub-Investigator- 1998.

RP54274X-320 “A Phase III Multicenter, Double-Blind, Parallel-Group, Placebo Controlled Study of the Effect of Riluzole 50 mg BID or 100 mg BID for Two Years on the Progression of Parkinson’s Disease in 1050 Patients.” -Sub-Investigator- 2000.

RP54274X-321 “A Phase III Multicenter, Double Blind, Parallel-Group Placebo Controlled Study of the Effect of Riluzole 50 mg BID or 100 mg BID on the Progression of Parkinson’s Disease in Patients Treated With L-DOPA or Dopamine Agonist” -Sub-Investigator - 2001.

Z/SEL/97/027 “An Open Extension Study of the Safety and Efficacy of Zydis Selegiline 1.25 to 2.5 mg Q.D. as an Adjunct in the Management of Parkinsonian Patients being treated with Levodopa.” -Sub-Investigator- 2003.

666E-CNS-0075-021 “A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients with Early Parkinson’s Disease.” Sub-Investigator – 2002-2003

M/2760/0011 “PNU-95666E: Open-Label, Long Term, Flexible Dose Study of Safety, Tolerability and Therapeutic Response in Patients with Parkinson’s Disease.” Sub-Investigator – 2003

DA2APD-0075-031 “A Phase III, Double-blind, Fixed Dose Response Study Comparing the Efficacy and Safely of Sumanirole vs. Placebo in Patients with Early Parkinson’s Disease.” Sub-Investigator – 2003

1198.100 NS2330 “A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson’s Disease Patients (Study for Poof of Concept in Early Parkinson’s Disease of a Triple Reuptake Inhibitor, NS2330 / SCEPTRE)”

02/AUG/2012

Parkinson's Disease *continued*

S308-3-003 " A Multi-Centre, Randomized, Double-Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson's Disease". Sub-Investigator, 2006

S308-3-008 "An extension of SLV308, A multicenter, randomized, double-blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of monotherapy in the treatment of patients with early stage Parkinson's disease." Sub-Investigator 2007

Droxidopa NOH306 "A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Parkinson's Disease" – 2010

S187.3.002 "A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments with Parkinson Medicinal Products, who Continue to Experience Persistent Motor Fluctuations" – 2010.

S187.3.003 "Open-Label, 12-Month Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects." – 2010.

S187.3.004 "An Open-Label, 12 Month Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations Despite Optimized Treatment with Available Parkinson's Disease Medications" – 2010

S187.3.005 "Open-Label Contiuation Treatment Study With Levodopa – Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuation Who Have Exhibited A Persistent And Positive Effect To Treatment in Previous Studies." – 2010.

Stroke

A-120-A "S*T*A*T stroke treatment with Ancrod (Arvin) trial, parallel, group sequential, double-blind, randomized, placebo-controlled study of the safety and efficacy of IV Ancrod (Arvin) given within 3 hours after the onset of acute ischemic stroke." -Principal Investigator - 1993 - 1998.

CAPRIE/P-1633 "Clopidogrel vs. aspirin in patients at risk of ischemic events" -Principal Investigator - 1993-1996.

510.1067 "Double-blind, randomized, placebo-controlled parallel-group trial of the efficacy and safety of Enlimomab Anti-Icam-1 compared to placebo administered within 6 hours of the onset of stroke symptoms, for treatment of acute ischemic stroke." -Sub-Investigator- 1995-1996.

534.11 "A phase II/III Multicenter, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of intravenous aptiganel hydrochloride in patients with an acute ischemic stroke" (Cerestat). -Sub-Investigator- 1996 - 1997.

IP302-007 "A placebo-controlled study to determine the effects of 500mg of Citicoline in ischemic stroke patients." -Sub-Investigator- 1996 – 1997.

03062k1-200-US "A randomized, double-blind, placebo-controlled parallel group multicenter trial of Fiblast®." -Sub-Investigator- October 1997- 1998.

Stroke *Continued*

SA-CMZ-009 “The Clomethiazole Acute Stroke Study in Ischemic Stroke (CLASS-I): A double blind, parallel group, multinational, multicenter study of the efficacy and safety of i.v.

Clomethiazole compared to placebo in patients with acute ischemic stroke.” -Sub-Investigator- 1998-2000.

SA-CMZ-0010 “ The Clomethiazole Acute Stroke Study in acute intracerebral hemorrhage (CLASS-H): A double blind, parallel group, multinational, multicenter study of safety of i.v. Clomethiazole compared to placebo in patients with acute intracerebral hemorrhage.” -Sub-Investigator- 1998-2000.

SA-CMZ-0011 “The Clomethiazole Acute Stroke Study in t-PA Treated Ischemic Stroke (CLASS-T): A double blind, parallel group, multinational, multicenter study of safety of i.v. Clomethiazole compared to placebo in patients treated with t-PA (tissue Plasminogen activator) for acute ischemic stroke.” -Sub-Investigator- 1998-2000.

YM872 “A Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study to evaluate the Safety of YM872 in Patients with Acute Ischemic Stroke.” -Sub-Investigator- 1998-2003.

981-124 “A double-blind, randomized, placebo-controlled study of Atorvastatin as prevention of cerebrovascular events in patients with a previous transient ischemic attack (TIA) or stroke” – Principal Investigator

SB 214857/030 BRAVO “Blockade of the GP IIB/IIIA receptor to avoid vascular occlusion.” – Principal Investigator – 1999.

CP101-606 MRI/DIFF/Perf. Stroke “A double-blind placebo controlled, multi-center study to evaluate the safety and efficacy of a 72-hour infusion of CP-101, 606 in subjects with acute ischemic stroke in the forebrain, study #161-106-5078.” –Principal Investigator- 2000.

GAIN-America- Protocol GLYA3002: An International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess over 3 Months the Safety, Efficacy and Pharmacoeconomics of an 800mg Loading Dose and Five 200mg Maintenance Doses of

GV150526 in the Treatment of Patients with a Clinical Diagnosis of Acute Stroke. -Sub-Investigator- 2001.

NF 198, 003 – “A Double-Blind, Placebo Controlled, Dose ranging Study of Nefiracetam in Patients with Post-Stroke Depression.” – Sub-Investigator – 2001

EFC7331 - **MATCH** – “**M**anagement of **At**herthrombosis with **C**lopidogrel in **H**igh-Risk Patients with Recent Transient Ischemic Attack or Ischemic Stroke: A Randomized, Double-Blind Study, with 18 months of Follow-up.” – Principal Investigator – 2001-2003.

003SE062601 – “A Randomized, Parallel Study to Assess the Outcomes of Treating obstructive Sleep Apnea (OSA) with Auto Set T in Patients Recovering from Stroke.” Sub-Investigator 2003

EFC4505 “Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) – Principal Investigator

02/AUG/2012

Stroke *continued*

CHARISMA EFC4505 “Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA).” 2002

Botox vs. Zanaflex “Placebo Controlled Trial of BOTOX ® versus Zanaflex ® for the Treatment of Subjects with Post- Stroke Upper Limb Spasticity” Principal Investigator March 2003

100282 Bayer Study “A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacolkinetic/Pharmacodynamic Effects of a Targeted

Exposure of Intravenous Repinotan in Patients with Acute Ischemic Stroke” Sub-Investigator, 2003

9.159 “PRoFESS – Prevention Regimen for Effectively avoiding Second Strokes: A double-blind, active and placebo controlled study of Aggrenox vs. clopidogrel, with and without Micardis”, Sub Investigator, 2004

SA-NXY-0007: “A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke”, Sub Investigator, 2004

Protocol Ptcl-01213 entitled: “A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel study to evaluate the effects of DP-b99 on Neurologic Function and Disability in subjects with Acute Ischemic Hemispheric Stroke , 2004

F7ICH-1641 A Randomized, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase® in Acute Intracerebral Hemorrhage, Sub-Investigator, 2005

NTI-ASP-0502 “A Randomized, Double-Blind, Placebo Controlled Study of Ancrod (Viprinex) in Subjects Beginning Treatment within 6 Hours of the Onset of Acute Ischemic Stroke”. Principal Investigator, 2006

CD-0125 “Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke”. Sub Investigator, 2006

NTS-INT06-007 “A Double-Blind, Randomized, Controlled, Parallel Group, Multi-Centre, Pivotal Study to Assess the Safety and Effectiveness of the Treatment of Acute Ischemic Stroke with the NeuroThera® Laser System within 24 Hours from Stroke Onset”. Principal Investigator, 2007

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50) P04737-3694”. Principal Investigator, 2007

P04737 “A multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a history of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events”, Sub-Investigator 2008.

_____
02/AUG/2012

Stroke *Continued*

01373 “A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset.” – 2010.

NTS-INT08-009 “ A double-blind, randomized, sham-controlled, parallel group, multicenter, pivotal study to assess the safety and efficacy of transcranial laser therapy with the NeuroThera® Laser System for the treatment of acute ischemic stroke within 24 hours of stroke onset.” – 2010.

Other

NAL0396 – “A Multicenter, randomized, double-blind, placebo-controlled, phase IIb study of oral Naloxone for the treatment of opioid-induced constipation in patients with chronic, non-malignant pain.” -Sub-Investigator- 1997-1998.

SR 90107A/ORG 31540 “ A Multicenter, randomized, parallel, double-blind, dose ranging study of subcutaneous SR 90107 A/ORG 31540 with an assessor blind, comparative control group of subcutaneous LMWH in the prevention of deep vein thrombosis after elective total hip replacement.” -Sub-Investigator- 1997.

K0718g”A phase III, Multicenter, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of recombinant human nerve growth factor (rhNGF) in subjects with diabetic neuropathy.” -Sub-Investigator- May 1997-1999.

97040B- “A Double Blind Randomized, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of 4 Doses of Intramuscular Phenoxybenzamine Hydrochloride Injection versus Placebo in Chronic Muscle Pain.” – Principal Investigator - 1998-1999.

GAL-IV-201-201X “A Multicenter, double-blind, randomized, placebo controlled, parallel group, clinical study of Galantamine/Chronic Fatigue.” –Principal Investigator- 2000.

DVT TRG004-02 & TRG004-03 “Prospective study of Venous Thromboembolism (VTE) patient characteristics, diagnostic methods and treatment plans in preparation for a phase III study” – Principal Investigator- 1999.

“Schneider (USA) Inc. Carotid Stent Therapy vs. Carotid Endarterectomy.” -Sub-Investigator-

191622-013-01 “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Clinical Study of the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin complex injections into Areas of Focal Tenderness in subjects with Chronic Low Back Pain.” -Sub-Investigator- 2000.

E2020-A001-209 “A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Preliminary Study to Determine the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Patients with Persistent Mild to Moderate Memory Impairments Resulting From a Single Closed Head Injury.” – Sub-Investigator – 2001

A1481066 – “A Multi-Center, Double-Blind, Placebo-Controlled Flexible Dose Study to Evaluate the Efficacy and Safety of Viagra ® in Women Who Have Female Sexual Arousal Disorder Resulting From a Traumatic Spinal Cord Injury.” – Sub-Investigator – 2003

02/AUG/2012

Other *continued*

GAL-COG-3002- “An Analysis of Mortality in Subjects who Participated in Three Studies of Galantamine in Mild Cognitive Impairment”, Principal-Investigator, 2004

101468/205: A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients with Restless Legs Syndrome, Sub-Investigator, 2005

E2020-A001-412: A One Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Subjects with Mild Cognitive Impairment, Sub-Investigator, 2005

FHP: “A Randomized Double-Blind Placebo Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Botulinum Neurotoxin Type A in the Treatment of Forward Head Posture

with Associated Chronic Tension Type Headache using a Novel Fixed site Injection Paradigm.” Sub-Investigator 2008

TIMI: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atheroscerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events.

CENA: A 24 week, prospective, randomized, parallel-group, double-blind, multi-center study comparing the effects of rivastigmine patch 15cm2 vs. rivastigmine patch 5cm2 on activities of daily living and cognition in patients with severe dementia of the Alzheimers type.

NXN-188: A phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache with Aura.

02/AUG/2012